 |
1 Disease |  |
0 Trials |
|
0 Trials |  |
6 News |  |
- || EVP-0334 / Forum Pharmaceuticals
Clinical, Journal, Epigenetic controller: Effect of the Histone Deacetylase Inhibitor FRM-0334 on Progranulin Levels in Patients With Progranulin Gene Haploinsufficiency: A Randomized Clinical Trial. (Pubmed Central) - Jan 14, 2022
P2
International multicenter clinical trials of FTD-GRN are feasible. ClinicalTrials.gov Identifier: NCT02149160.
- | EVP-0334 / Forum Pharmaceuticals
Enrollment closed, Trial primary completion date, Epigenetic controller: Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation (clinicaltrials.gov) - Mar 23, 2016
P2, N=30, Active, not recruiting, Sponsor: FORUM Pharmaceuticals Inc
ClinicalTrials.gov Identifier: NCT02149160. Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2016 --> Aug 2016
- EVP-0334 / Forum Pharmaceuticals
Enrollment open, Epigenetic controller: Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation (clinicaltrials.gov) - Oct 22, 2014
P2, N=30, Recruiting, Sponsor: FORUM Pharmaceuticals Inc
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2016 --> Aug 2016 Not yet recruiting --> Recruiting
- EVP-0334 / Forum Pharmaceuticals
New P2 trial, Epigenetic controller: Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation (clinicaltrials.gov) - May 27, 2014
P2, N=30, Not yet recruiting, Sponsor: FORUM Pharmaceuticals Inc